Evolus (NASDAQ:EOLS) Hits New 1-Year High – Time to Buy?

Shares of Evolus, Inc. (NASDAQ:EOLS) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $17.81 and last traded at $17.78, with a volume of 358373 shares. The stock had previously closed at $16.90.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on EOLS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, October 3rd. Finally, Barclays raised their target price on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, September 13th.

Evolus Trading Up 2.0 %

The stock’s fifty day moving average price is $15.49 and its 200 day moving average price is $13.37. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The stock has a market cap of $1.08 billion, a PE ratio of -16.82 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to analysts’ expectations of $65.06 million. On average, sell-side analysts forecast that Evolus, Inc. will post -0.64 EPS for the current year.

Insider Buying and Selling

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently bought and sold shares of EOLS. Quest Partners LLC purchased a new position in shares of Evolus in the 2nd quarter worth $43,000. Quarry LP purchased a new position in shares of Evolus in the 2nd quarter worth $54,000. Sierra Summit Advisors LLC purchased a new position in shares of Evolus in the 4th quarter worth $119,000. Profund Advisors LLC purchased a new position in shares of Evolus in the 2nd quarter worth $130,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 65.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company’s stock worth $154,000 after buying an additional 4,355 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.